FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

被引：0
|
作者：
Le, Xiuning
Spira, Alexander I.
Gadgeel, Shirish M.
Riess, Jonathan W.
Yu, Yan
Zhao, Yanqiu
Cheng, Ying
Juan-Vidal, Oscar
Gao, Bo
Yoh, Kiyotaka
Forster, Martin
Kitazono, Satoru
Hayashi, Hidetoshi
Planchard, David
Jiang, Yong
Baio, Nichole
Kowanetz, Marcin
Leung, William
Hsu, Jerry Y.
Wang, Jie
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] NEXT Oncol Virginia, Fairfax, VA USA
[3] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA
[4] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[5] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Jilin Canc Hosp, Changchun, Peoples R China
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Blacktown Hosp, Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[10] Natl Canc Ctr Hosp East, Kashiwa, Japan
[11] UCL, Hosp NHS Trust, Canc Inst, London, England
[12] Japanese Fdn Canc Res JFCR, Canc Inst Hosp, Tokyo, Japan
[13] Kindai Univ Hosp, Osaka, Japan
[14] Gustave Roussy, Dept Med Oncol, Thorac Grp, Villejuif, France
[15] Allist Pharmaceut, Shanghai, Peoples R China
[16] ArriVent Biopharma, Newtown, PA USA
[17] ArriVent Biopharma, Burlingame, CA USA
[18] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8666
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy
    Jinpeng Shi
    Hui Yang
    Tao Jiang
    Xuefei Li
    Chao Zhao
    Limin Zhang
    Sha Zhao
    Xiaozhen Liu
    Yijun Jia
    Yan Wang
    Lei Xi
    Shijia Zhang
    Chunxia Su
    Shengxiang Ren
    Caicun Zhou
    ChineseJournalofCancerResearch, 2017, 29 (06) : 543 - 552
  • [22] Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
    Kaen, D.
    Tsou, F.
    Lupinacci, L.
    Puparelli, C.
    Minatta, J.
    Rizzo, M.
    Berutti, S.
    Di Giovanni, R.
    Ferreira, Y.
    Recondo, G.
    Carranza, O.
    Flores, M.
    Aman, E.
    Di Mario, G.
    Pini, A.
    Castagneris, N.
    Roa, M.
    Enrico, D.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S668
  • [23] Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
    Wang, P.
    Li, Y.
    Lv, D.
    Ding, L.
    Hong, W.
    Han-Zhang, H.
    Lin, J.
    Zhou, J.
    Wang, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S599
  • [24] Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [25] Intercalated EGFR and Chemotherapy in Locally Advanced NSCLC with EGFR Mutations: Data on 5 Patients and Clinical Study
    Griesinger, Frank
    Roeper, Julia
    Lueers, Anne
    Falk, Markus
    Hallas, Cora
    Tiemann, Markus
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S871 - S871
  • [26] Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
    Geng, R.
    Chen, Y.
    Miao, J.
    Liu, H.
    Qin, Y.
    Han, Z.
    Li, S.
    Guan, Y.
    Wu, H.
    Zhao, Y.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S120 - S121
  • [27] EGFR MUTATIONS IN NSCLC PATIENTS IN CENTRAL EUROPE: THE INSIGHT OBSERVATIONAL STUDY
    Pirker, Robert
    Dziadziuszko, Rafal
    Berzinec, Peter
    Dusek, Ladislav
    Cufer, Tanja
    Bajcic, Paolo
    Popper, Helmut
    Olszewski, Wlodzimierz
    Chorostowska-Wynimko, Joanna
    Skrickova, Jana
    Kolek, Vitezslav
    Pesek, Milos
    Ostoros, Gyula
    Chmielewska, Izabela
    Medvecova, Lenka
    Eisterer, Wolfgang
    Kandrnal, Vit
    Mazal, Juraj
    Popper, Helmuth
    Olszewski, Wlodzimierz
    Ramlau, Rodryg
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S897 - S897
  • [28] Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients
    Wang, H.
    Xing, R.
    Niu, Y.
    Zhang, M.
    Zhang, X.
    Li, M.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S398 - S399
  • [29] Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
    Xueyun Tan
    Yuan Li
    Sufei Wang
    Hui Xia
    Rui Meng
    Juanjuan Xu
    Yanran Duan
    Yan Li
    Guanghai Yang
    Yanling Ma
    Yang Jin
    Respiratory Research, 23
  • [30] Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
    Popat, Sanjay
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Park, Cheol Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Marten, Angela
    Miura, Satoru
    ONCOLOGIST, 2022, 27 (04) : 255 - 265
12345